Paper Details

  1. Home
  2. Paper Details

Efficacy and safety of the bisphosphonate tiludronate for the treatment of tumor-associated hypercalcemia.

Author: BodyJ J, DumonJ C, MagritteA

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Tiludronate, a bisphosphonate, was evaluated for the treatment of hypercalcemia in 19 cancer patients. While effective in lowering serum calcium levels, high intravenous doses were potentially nephrotoxic. Oral tiludronate administration was less effective and associated with nausea, vomiting, and an increase in serum creatinine levels. Tiludronate is not recommended for the treatment of tumor-associated hypercalcemia.
Paper Details　
Original Abstract of the Article :
Tiludronate is a new bisphosphonate whose efficacy has already been reported for the prevention of postmenopausal bone loss. We have evaluated its efficacy and tolerance by a dose-finding study in 19 hypercalcemic cancer patients after adequate intravenous (iv) rehydration. Treatment consisted of 3 ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/0169-6009(91)90131-i

データ提供：米国国立医学図書館（NLM）

Efficacy and Safety of the Bisphosphonate Tiludronate for the Treatment of Tumor-Associated Hypercalcemia

The treatment of [tumor-associated hypercalcemia] is an area of active research and development. This study investigates the efficacy and safety of [tiludronate], a bisphosphonate, in the treatment of hypercalcemia. It aims to evaluate the effectiveness of this drug and assess its potential risks and side effects. This research is a valuable contribution to the field of cancer treatment, offering insights into the use of bisphosphonates in managing a common complication of cancer.

Tiludronate for Tumor-Associated Hypercalcemia: Efficacy and Safety

The study reveals that tiludronate can effectively reduce serum calcium levels in patients with tumor-associated hypercalcemia. However, the need for high intravenous doses raises concerns about potential nephrotoxicity. The study also highlights the importance of careful monitoring for side effects, including increases in serum phosphate and creatinine levels.

Weighing the Benefits and Risks: Informed Decision-Making

This study underscores the importance of weighing the benefits and risks of any treatment option. While tiludronate demonstrates efficacy in reducing calcium levels, it is crucial to consider potential side effects and the overall impact on patient health. This research emphasizes the need for careful patient selection and close monitoring during treatment.

Dr.Camel's Conclusion

This research is like a desert oasis, offering relief from the challenges of tumor-associated hypercalcemia. It reveals the potential benefits of tiludronate in reducing calcium levels but also highlights the importance of considering its potential risks. Balancing efficacy with safety is key to providing optimal care for patients with this condition.

Date :
  1. Date Completed 1992-03-04
  2. Date Revised 2019-10-28
Further Info :

Pubmed ID

1773138

DOI: Digital Object Identifier

10.1016/0169-6009(91)90131-i

Related Literature

Article Analysis
・Effects of tiludronate
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.